Evidence map›Paper›PMID 42176196›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

An interpretable

Shuaitao Xiong, Jiangyu Ma, Han Li, Hui Zhu, Jingxin Yang, Zhengtong Lv, Huimin Hou, Xin Ding, Jia Chen, Yi Liu and 8 more

Abstract readMulticenter StudyValidation Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shuaitao Xiong *Department of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Jiangyu Ma *Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational nuclear medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Han Li *Department of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Hui ZhuDepartment of Nuclear Medicine, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Jingxin YangDepartment of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Zhengtong LvDepartment of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Huimin HouDepartment of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Xin DingDepartment of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Jia ChenDepartment of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Yi LiuDepartment of Urology, Peking University First Hospital, Beijing, China.
Wenrui XuDepartment of Radiology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Chunmei LiDepartment of Radiology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Longteng LiuDepartment of Pathology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Wei ZhangDepartment of Pathology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Kan GongDepartment of Urology, Peking University First Hospital, Beijing, China.
Miao WangDepartment of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. wmwfdsgjzx@163.com.
Li HuoDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational nuclear medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. huoli@pumch.cn.
Ming LiuDepartment of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. liumingbjh@126.com.ORCID 0000-0002-4770-4449

Funding

Chinese Academy of Medical Sciences Initiative for Innovative Medicine 2025-I2M-C&T-B-093National High Level Hospital Clinical Research Funding BJ-2022-115National High Level Hospital Clinical Research Funding BJ-2023-105Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2023-JKCS-22
6 · The paper itself

Abstract

purposeDistinguishing indolent from clinically significant prostate cancer (csPCa) in biopsy-naïve men remains a diagnostic challenge, often leading to unnecessary biopsies. This study aimed to develop and externally validate an interpretable multimodal model integrating

methodsThis multicenter retrospective study analyzed 302 biopsy-naïve patients derived from a prospective multicenter cohort. Radiomic features were extracted from

resultsThe Fusion model demonstrated robust diagnostic efficacy, achieving AUCs of 0.92 in both the internal (95% CI: 0.85-0.97) and external (95% CI: 0.83-0.99) validation cohorts. In the PI-RADS 3 subgroup, the model outperformed standard clinical assessments, yielding an excellent AUC of 0.97 (sensitivity 95.0%, specificity 86.5%). Clinically, risk stratification utilizing the Fusion model could avoid 82.9%, 75.0%, and 72.2% of unnecessary biopsies across the three cohorts, while maintaining low missed-diagnosis rates of 4.0%, 9.5%, and 6.1%, respectively. Furthermore, SHAP analysis identified PET-derived intensity and textural features as the dominant predictors, underscoring the indispensable added value of

conclusionThis interpretable Fusion model integrating

Indexed as

Edetic AcidMagnetic Resonance ImagingOligopeptidesPositron Emission Tomography Computed TomographyProstateProstatic NeoplasmsRadiomicsAgedBiopsyGlutaratesHumansMaleMiddle AgedPhosphinic AcidsRetrospective Studies(18)F-PSMA-11Edetic AcidGlutaratesOligopeptidesPhosphinic AcidsBiopsy-naïveProstate cancerPSMA PET/CTRadiomicsRisk stratification

Identifiers

PMID42176196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.